Theraclion Stock

Equities

ALTHE

FR0010120402

Advanced Medical Equipment & Technology

Market Closed - Euronext Paris 11:35:29 2024-04-26 EDT 5-day change 1st Jan Change
0.36 EUR -1.10% Intraday chart for Theraclion +4.35% -7.22%

Financials

Sales 2021 1.48M 1.58M 2.16M Sales 2022 1.24M 1.32M 1.81M Capitalization 26.15M 27.96M 38.22M
Net income 2021 -3M -3.21M -4.39M Net income 2022 -4M -4.28M -5.85M EV / Sales 2021 24.8 x
Net Debt 2021 6.99M 7.47M 10.21M Net Debt 2022 6.52M 6.97M 9.53M EV / Sales 2022 26.4 x
P/E ratio 2021
-7.93 x
P/E ratio 2022
-5.35 x
Employees 30
Yield 2021 *
-
Yield 2022
-
Free-Float 71.21%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.10%
1 week+4.35%
Current month-5.26%
1 month-5.76%
3 months-29.96%
6 months-24.21%
Current year-7.22%
More quotes
1 week
0.35
Extreme 0.35
0.37
1 month
0.34
Extreme 0.339
0.39
Current year
0.31
Extreme 0.308
0.68
1 year
0.30
Extreme 0.3
0.85
3 years
0.30
Extreme 0.3
2.28
5 years
0.30
Extreme 0.3
2.76
10 years
0.30
Extreme 0.3
14.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 19-12-31
Director of Finance/CFO - -
Chief Operating Officer - -
Members of the board TitleAgeSince
Director/Board Member - 19-02-12
Director/Board Member - 18-01-31
Chairman 67 22-01-23
More insiders
Date Price Change Volume
24-04-26 0.36 -1.10% 7,377
24-04-25 0.364 +0.55% 9,649
24-04-24 0.362 +0.56% 13
24-04-23 0.36 0.00% 7,709
24-04-22 0.36 +4.35% 1,383

Real-time Euronext Paris, April 26, 2024 at 11:35 am

More quotes
Theraclion specializes in developping, manufacturing and marketing echotherapy equipment associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules.Net sales break down by activity as follows: - sale of equipment (61.8%); - sale of consumables (29%); - provision of after-sales services (9.2%). Export accounts for 99.7% of net sales.
More about the company

Annual profits - Rate of surprise